The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of cognitive deficits in Major Depressive Disorder (MDD) remains an important unmet need. This meta-analysis evaluated the effects of vortioxetine on cognition in patients with MDD. METHODS: Random effects meta-analysis was applied to three randomized, double-blind, placebo-controlled 8-week trials of vortioxetine (5-20mg/day) in MDD, and separately to two duloxetine-referenced trials. The primary outcome measure was change in Digit Symbol Substitution Test (DSST) score. Standardized effect sizes (SES) versus placebo (Cohen's d ) were used as input. Path analysis was employed to determine the extent to which changes in DSST were mediated independently of a change in Montgomery-Åsberg Depression Rating Scale (MADRS) score. Meta-analysis was applied to MADRS-adjusted and -unadjusted SES values. Changes on additional cognitive tests were evaluated (source studies only). RESULTS: Before adjustment for MADRS, vortioxetine separated from placebo on DSST score (SES 0.25-0.48; nominal p < 0.05) in all individual trials, and statistically improved DSST performance versus placebo in meta-analyses of the three trials (SES = 0.35; p < 0.0001) and two duloxetine-referenced trials (SES = 0.26; p = 0.001). After adjustment for MADRS, vortioxetine maintained DSST improvement in one individual trial ( p = 0.001) and separation from placebo was maintained in meta-analyses of all three trials (SES = 0.24; p < 0.0001) and both duloxetine-referenced trials (SES 0.19; p = 0.01). Change in DSST with duloxetine failed to separate from placebo in individual trials and both meta-analyses. Change in DSST statistically favored vortioxetine versus duloxetine after MADRS adjustment (SES = 0.16; p = 0.04). CONCLUSIONS: Vortioxetine, but not duloxetine, significantly improved cognition, independent of depressive symptoms. Vortioxetine represents an important treatment for MDD-related cognitive dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical studies of patients with MDD, vortioxetine has shown significant and clinically relevant effects not only on depressive symptoms, but also on the physical and cognitive symptoms of depression (Christensen et al., 2018a;Kelliny et al., 2015;McIntyre et al., 2016).”
From Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment (2021) · cites this paper as McIntyre et al., 2016
Experimental — accuracy not yet measuredIn the citing paper
“Hitherto, only 2 antidepressants (ie, duloxetine and vortioxetine) have demonstrated direct, independent, and clinically relevant effects on cognitive dysfunction in MDD. 8”
From Cognitive Impairment in Major Depressive Disorder (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“The I2 value in the meta-analysis of unadjusted data for the three trials was 42% (data not shown), indicating a low likelihood that study heterogeneity had a relevant impact on effect estimates (Higgins et al., 2003).”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 2×
“These were similarly designed, 8-week, randomized, double-blind, placebo-controlled trials in patients who met the Diagnostic and Statistical Manual of Mental Disorders criteria for recurrent MDD (Fourth Edition, Text Revision; DSM-IV-TR; American Psychiatric Association, 2000b) and had a MADRS (Montgomery and Åsberg,…”
BackgroundMethodCognitive impairment in depression: a systematic review and meta-analysis
Rock, P. L., Roiser, J. P., Riedel, W. J., & Blackwell, A. D. (2014) · Psychological Medicine · doi:10.1017/s0033291713002535 · Cited by 2,161 · cited 1×
“7 (Lee et al., 2012; Snyder, 2013; Rock et al., 2014), a magnitude of cognitive decline that is anticipated to have a profound impact on occupational and school performance.”
BackgroundSnyder, H. R. (2013) · Psychological Bulletin · doi:10.1037/a0028727 · Cited by 1,667 · cited 2×
“…tests) observed in patients with MDD relative to healthy controls, for which metaanalyses indicate that the typical SES are 0.2–0.7 (Lee et al., 2012; Snyder, 2013; Rock et al., 2014), a magnitude of cognitive decline that is anticipated to have a profound impact on occupational and school…”
BackgroundInfluentialDistributed Disturbances in Brain Structure and Function in Schizophrenia
(2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.1 · Cited by 969
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Self-citationA meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.023 · Cited by 737 · cited 1×
“7 (Lee et al., 2012; Snyder, 2013; Rock et al., 2014), a magnitude of cognitive decline that is anticipated to have a profound impact on occupational and school performance.”
Background
Research works printed but not linked: 1
- Ditlevsen S Christensen U Lynch J Damsgaard MT Keiding N (2005b). The mediation proportion: a structural equation approach for estimating the proportion of exposure effect on outcome explained by an intermediate variable. Appendix A, The mediation proportion: details of the basic statistical regression model. Epidemiology 16: 114– 120. 15613954 · DOI · Paper page
Cited by
Items 101–187 of 187
Sharp, A. M., Lertphinyowong, S., Yee, S. S., Paredes, D., Gelfond, J., Johnson‐Pais, T. L., Leach, R. J., Liss, M. A., Risinger, A. L., Sullivan, A. C., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05274-4 · Cited by 12
Danielak, D. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1880567 · Cited by 12
“unique properties, such as enhancing cognitive function [8,9].”
BackgroundDunlop, B. W., Rakofsky, J. J., Newport, D. J., Mletzko, T., Barone, K., Nemeroff, C. B., & Harvey, P. D. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001363 · Cited by 12
Gamberini, G., Masuccio, F. G., Ferriero, G., Cattaneo, D., & Solaro, C. M. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.02.075 · Cited by 10
Segura‐Garcìa, C., Rania, M., Carbone, E. A., de Filippis, R., Aloi, M., Caroleo, M., Grasso, G., Calabrò, G., Fazia, G., Staltari, F. A., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.635502 · Cited by 10
Wang, X., Wang, R., Zhang, Z., Luo, C., Zhao, Z., Ruan, J., Huang, R., Zhang, H., Wu, Q., Yu, S., et al. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03351-6 · Cited by 12
“Delayed testing is typically done after the completion of animal’s fluency and DSST tests.”
BackgroundMethodInfluentialChristensen, M. C., Cañellas, F., Loft, H., & Montejo, A. L. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s473056 · Cited by 11
Self-citationXiong, S., Li, W., Zhou, Y., Ren, H., Lin, G., Zhang, S., & Xiang, X. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.950885 · Cited by 10
“Based on previous studies that reported the modulating effect of vortioxetine on cognitive function and local brain signal (32), we hypothesized that vortioxetine modulates ALFF in MDD patients.”
BackgroundBerardelli, I., Rogante, E., Formica, F., Iannazzo, R., mammoliti, A. V., Riccioni, R., Veizi, S., McIntyre, R. S., & Pompili, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811241309612 · Cited by 8
“…also in elderly patients; moreover, it has been shown to significantly benefit measures of cognitive function, anhedonia, emotional blunting, fatigue, as well as motivationalrelated complaints (Bishop et al., 2021; Christensen et al., 2023a, 2024; McIntyre et al., 2014, 2016, 2021, 2024).”
Self-citationNicola, M. D., Adair, M., Rieckmann, A., & Cronquist Christensen, M. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241260996 · Cited by 10
“…experienced by patients with MDD, including depressive, cognitive, and physical symptoms, as well as anxiety and functional impairment (Baldwin et al., 2016; Christensen et al., 2018; Christensen et al., 2023a; Iovieno et al., 2021; McIntyre et al., 2016; McIntyre et al., 2021; Thase et al., 2016).”
BackgroundGil-Sánchez, A., Canudes, M., Valcheva, P., Nogueras, L., González‐Mingot, C., Hervás, J. V., Peralta, S., Solana, M. J., & Brieva, L. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230321093133 · Cited by 10
Kognitive Störungen bei Patienten mit Depression
Schilling, T. M., Bossert, M., Weisbrod, M., & Aschenbrenner, S. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01074-4 · Cited by 10
McIntyre, R. S., Lipsitz, O., Rodrigues, N. B., Subramaniapillai, M., Nasri, F., Lee, Y., Fehnert, B., King, J., Chrones, L., Kratiuk, K., et al. (2022) · JMIR Mental Health · doi:10.2196/33871 · Cited by 7
“In fact, DSST has been effectively used to assess improved performance in patients with MDD when comparing 2 different antidepressants [5,29].”
BackgroundMethodInfluentialSelf-citationScreening and measurement of cognitive impairment in psychiatry
Harrison, J. (2019) · CNS Spectrums · doi:10.1017/s1092852918001657 · Cited by 10
Self-citationChristensen, M. C., Schmidt, S. N., & Grande, I. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.07.018 · Cited by 6
Mattingly, G. W., Brunner, E., Chrones, L., Lawrence, D. F. E., Simonsen, K., & Ren, H. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.977560 · Cited by 10
“Randomized clinical trials of vortioxetine therapy for patients with MDD have demonstrated efficacy and safety, as well as improved overall and cognitive functioning (8, 15, 16).”
BackgroundKwan, A. T. H., Guo, Z., Ceban, F., Le, G. H., Wong, S., Teopiz, K. M., Rhee, T. G., Ho, R., Vincenzo, J. D. D., Badulescu, S., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02826-9 · Cited by 7
“Vortioxetine was selected as the intervention for this study on the basis that it has demonstrated multi-domain efficacy in improving measures of cognition, mood, reward function, and positive valence systems [19, 20].”
Self-citationHillhouse, T. M., Merritt, C. R., Smith, D. A., Cajina, M., Sánchez, C., Porter, J. H., & Pehrson, A. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01024 · Cited by 7
Anhedonia as a basic syndrome and a target for treatment for depressive disorder
Mazo, G. E., & Kibitov, A. O. (2019) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2019-3-10-18 · Cited by 10
Wang, G., Zhao, K., Reynaud-Mougin, C., Loft, H., Ren, H., Eriksen, H. F., & Ettrup, A. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1723072 · Cited by 8
Self-citationChristensen, M. C., Grande, I., Rieckmann, A., & Chokka, P. R. (2024) · CNS Spectrums · doi:10.1017/s1092852924000610 · Cited by 6
Almeida, S. S., Christensen, M. C., Simonsen, K., & Adair, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221132468 · Cited by 7
“…(5–20 mg administered orally once daily) has demonstrated broad efficacy against the symptoms of MDD (Gonda et al., 2019; Thase et al., 2016), and vortioxetine-treated patients have shown significant improvements in cognition and overall functioning (Florea et al., 2017; McIntyre et al., 2016).”
BackgroundBobrov, A. E., Krasnoslobodtseva, L. A., & Mutnykh, E. M. (2017) · Journal of psychiatry · doi:10.4172/2378-5756.1000417 · Cited by 7
“Differences between classes of antidepressants have been posited [16] and reports on bupropion [17] and vortioxetine [18] encourage the view that the pharmacodynamic profiles of individual drugs may produce clinically pertinent differences between antidepressants.”
BackgroundPolosan, M., Rabbani, M., Christensen, M. C., Simonsen, K., & Ren, H. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s374635 · Cited by 6
Memory and attention deficit in chronic migraine
Владимировна, Л. Н., Filatova, E. G., & Osipova, D. V. (2018) · Neuromuscular Diseases · doi:10.17650/2222-8721-2018-8-2-10-16 · Cited by 9
“В 3 крупных плацебо-контролируемых исследованиях лечение вортиоксетином приводило к клинически значимому субъективному и объективному улучшению памяти, ИФ, внимания и повышению скорости обработки информации [12, 13].”
Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial
Mills, N. T., Sampson, E., Fourrier, C., & Baune, B. T. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa092 · Cited by 6
“Vortioxetine has been found to have efficacy in the treatment of MDD as well as in the prevention of relapse (Boulenger et al., 2012; Katona and Katona, 2014).”
BackgroundInfluentialThe dose-response relationship of vortioxetine on major depressive disorder: an umbrella review
Wang, P., Wang, W., Liu, Y., Li, W., Hu, J., Su, Y., Li, J., Li, N., & Si, T. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116118 · Cited by 6
“…vortioxetine has been supported to have positive impact on cognitive functions (Zhang et al. 2022; Huang et al. 2022; Iovieno et al. 2021; McIntyre et al. 2016; Li et al double-blind placebo-controlled trials, after adjustment for MADRS, vortioxetine maintained separation from placebo in…”
García‐Alberca, J. M., de la Guía, P., Gris, E., Mendoza, S., de la Rica, M. L., Barbancho, M. Á., Lara, J. P., & Blanco‐Reina, E. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090918 · Cited by 7
Zhang, Y., Song, Z., Zhang, H., Lin, H., Xu, P., Li, Z., He, Q., & Wei, B. (2025) · Biomedicines · doi:10.3390/biomedicines13051081 · Cited by 6
“These findings provide robust evidence for the use of vortioxetine in the treatment of MDD [115].”
Experience with vortioxetine in the treatment of post-stroke depression
Strelnikova, I. A., Светкина, А. А., Minina, Y. D., & Androfagina, O. V. (2020) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2020-1-45-49 · Cited by 5
Wang, G., Si, T., Rieckmann, A., Ma, J., & Christensen, M. C. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s460408 · Cited by 5
Neurotic depression: approaches to treatment
Volel, B. A., & Sorokina, O. Y. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20191191269 · Cited by 6
Vaiana, A. M., Chen, Y., Gelfond, J., Johnson‐Pais, T. L., Leach, R. J., Ramamurthy, C., Thompson, I. M., & Morilak, D. A. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02600-5 · Cited by 5
“These effects were independent of its antidepressant effects [12].”
BackgroundHarrison, J., & Hendrix, S. B. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00021-7 · Cited by 5
Self-citationSystematic review of gender bias in vortioxetine clinical trials
Santos-Casado, M., Guisado-Gil, A. B., & Santos‐Ramos, B. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110088 · Cited by 5
Managing interactions between cognitive enhancers and other psychotropics
Tang, S. W., Tang, W. H., & Leonard, B. E. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000172 · Cited by 3
Subhas, N., Ang, J. K., Tan, K., & Ahmad, S. N. A. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2149415 · Cited by 5
Kwan, A. T. H., Le, G. H., Guo, Z., Ceban, F., Teopiz, K. M., Rhee, T. G., Ho, R., Vincenzo, J. D. D., Badulescu, S., Meshkat, S., et al. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00494-1 · Cited by 6
Self-citationEmerging drugs for the treatment of major depressive disorder
Hong, J., Vernon, D., Kunovac, J. L., & Stahl, S. M. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2117297 · Cited by 5
“cognitive functioning and processing speed [20] with a reduced incidence of sexual dysfunction [7].”
BackgroundVaiana, A. M., Asher, A. M., Tapia, K., & Morilak, D. A. (2023) · Neuroendocrinology · doi:10.1159/000535365 · Cited by 3
McIntyre, R. S. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2522885 · Cited by 4
Self-citationZajecka, J., Laufer, O., Peremen, Z., Sholtes, D., Mackey, I., Baumeister, C., White, A., Geva, A. B., & Issachar, G. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100732 · Cited by 3
Badr, B., Gailani, H. A., Alkhoori, S. A., Butt, H., Daher, M., Dheyaa, B., Hindy, N. E., Eid, M., Elsaadouni, N., Faia, V., et al. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00526-w · Cited by 3
Hochstrasser, B., Hasler, G., Baumann, A., Bose, R., Reines, E., Kammerer, M., & Sousek, A. (2025) · CNS Drugs · doi:10.1007/s40263-025-01207-2 · Cited by 3
“Vortioxetine has also been associated with improvements in cognition and overall functioning [12, 35–38].”
Rajathei, D. M., Parthasarathy, S., & Selvaraj, S. (2018) · Current Computer - Aided Drug Design · doi:10.2174/1573409914666181011144810 · Cited by 4
Cuomo, A., Barillà, G., Cattolico, M., Pardossi, S., Mariantoni, E., Koukouna, D., Carmellini, P., & Fagiolini, A. M. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2333394 · Cited by 3
“Beyond isolated short-term RCTs, the cognitive-improving properties of vortioxetine have been validated in three meta-analyses [7,58,59] and one open-label study [60] in which cognitive function was reported as the primary outcome variable.”
BackgroundMurthy, N. V., Xu, R., Zhong, W., & Harvey, P. D. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.025 · Cited by 2
Treating Holmes tremor with deep brain stimulation
Nevrlý, M., Krahulík, D., Otruba, P., Bardoň, J., & Kaňovský, P. (2020) · Neurologie pro praxi · doi:10.36290/neu.2019.071 · Cited by 2
Sahakian, B. J., d’Angelo, L.-S. C., & Savulich, G. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108565738.007 · Cited by 3
Chung, A. K. K., Tse, C. Y., Yeung, G. K. Y., Tang, S. W., Chan, W.-M., & Law, J. K. C. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209607 · Cited by 1
Pavlova, T. A., Telepina, M. A., Perelygin, V. V., Smetannikova, E. A., Sklyarova, N. A., & Orlova, A. V. (2025) · Pharmacy Formulas · doi:10.17816/phf686915 · Cited by 3
Efficacy and adverse effect profile of vortioxetine in major depressive disorder: A meta-analysis
Vijayan, S., Ramanathan, B., Mohan, R., Venkatesan, V., Selvaraj, A., & Coumaravelou, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251375106 · Cited by 1
“Vortioxetine is known to have a better impact on the cognitive dysfunction associated with MDD, and its effect was found to be independent of the depressive symptoms (McIntyre et al., 2016).”
Is vortioxetine as preferable a molecule as duloxetine in depressed patients with fibromyalgia?
Aker, D. A., & Öke, D. (2025) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2025.09.004 · Cited by 1
Kobayashi, Y., Hirano, J., Nakagawa, A., Takemura, R., Umeda, S., 田島, 美., Noda, S., Amano, M., Kamiya, K., Mimura, M., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121632 · Cited by 1
Neurobiological Aspects of Functional Recovery in Major Depressive Disorder
Chakrabarty, T., Sarfati, D., & Lam, R. W. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00024-x · Cited by 2
The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
Harrison, J. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.025 · Cited by 1
Self-citationTranslational Medicine Strategies in Drug Development for Mood Disorders
Pan, Z., Grovu, R. C., & McIntyre, R. S. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00023-0 · Cited by 2
Self-citationA “Real-World” Chart Review Study of Monotherapy and Adjunctive Vortioxetine in Clinical Practice
Karia, S., Sousa, A. D., & Syeda, R. (2021) · Indian Journal of Private Psychiatry · doi:10.5005/jp-journals-10067-0059 · Cited by 1
Vortioxetine: An antidepressant apart?
Greener, M. (2016) · British Journal of Mental Health Nursing · doi:10.12968/bjmh.2016.5.4.148
Hamati, R. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-24287
“Vortioxetine is unique amongst the drugs with intrinsic antidepressant activity, as it has been reported to improve cognitive functioning irrespective of depressive symptoms (McIntyre et al., 2016), possibly due to 5-HT3 and 5-HT7 antagonistic action (Leiser et al., 2014).”
BackgroundRodrigues, N. B. (2020) · TSpace (University of Toronto)
Laux, G. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_114-1
Current Treatments for Depression
Krystal, J. H., & Charney, D. S. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0031
Mechanisms of action and clinical effects of vortioxetine
Петрова, Н. Н., & Mukhin, A. A. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212206284
Laux, G. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_114
Depression in the elderly – the position of vortioxetine
Staniec-Kutera, M., & Waszkiewicz, N. (2023) · Psychiatria Spersonalizowana · doi:10.5114/psychs.2023.135565 · Cited by 3
Kwan, A. T. H., Lakhani, M., Le, G. H., Singh, G., Teopiz, K. M., Guo, Z., Manku, A. S., Rosenblat, J. D., & McIntyre, R. S. (2024) · medRxiv · doi:10.1101/2024.03.18.24304375
Self-citationDesfossés, C. Y., & Blier, P. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as16
Guidetti, C., Chaikali, S., Trivedi, M. H., Shelton, R. C., Iosifescu, D. V., Thase, M. E., Jha, M. K., Mathew, S. J., DeBattista, C., Dokucu, M. E., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119836 · Cited by 2
Watanabe, K., Sumiyoshi, T., Kato, M., Kikuchi, T., Moriguchi, Y., Åström, D. O., & Christensen, M. C. (2025) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2025.100955 · Cited by 2
Çoban, C., & Bulut, S. D. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116778
Derakhshan, D., Lipsman, N., Feinstein, A., LEVITT, A. J., Eizenman, M., Rabin, J. S., & Giacobbe, P. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2025.1696560 · Cited by 1
McCue, M., Sarkey, S., Eramo, A., François, C., & Parikh, S. V. (2021) · Figshare · doi:10.6084/m9.figshare.17162849
Papalexi, E., Galanopoulos, A., Kontis, D., Markopoulou, M., Balta, G., Karavelas, E., Panagiotidis, P., Vlachos, T., & Ettrup, A. (2022) · Figshare · doi:10.6084/m9.figshare.20484658
McCue, M., Sarkey, S., Eramo, A., François, C., & Parikh, S. V. (2021) · Figshare · doi:10.6084/m9.figshare.17162846
Pharmacological treatment of adolescent depression: Current advances and future perspectives
Li, Y., Wang, F., Chen, G., & Zhai, S. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100278 · Cited by 3
Kammerer, M. H., Hasler, G., Hochstrasser, B., Baumann, A., & Sousek, A. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01537-z
“…domains of everyday functioning — cognition, professional activities, family, social and leisure activities, physical well-being and quality of life — were observed, which is consistent with findings from previous clinical trials and real-world studies for vortioxetine [14, 16, 17, 35, 38, 39, 57].”
InfluentialPrelog, P. R., Plesnicar, B., Zupan, M., Frol, S., & Kramberger, M. G. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2653170
“Vortioxetine, which has pro-cognitive effects in major depression and mild cognitive impairment (MCI), is conceptually attractive in AD [43,44], and open-label phase II data in MCI and small dementia cohorts suggest improvements in certain cognitive domains [5] but no large phase-3 trials in…”
Cognitive Dysfunction and Suicide
Sunzeri, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_19
Ramachandran, T., Ng, C. G., Wong, J. J. I., & Adlan, A. S. A. (2026) · Pharmacoepidemiology · doi:10.3390/pharma5020014
Laval, M. D. F., Arellano, J. M., & Amador, M. S. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122281
El-Kassem, M., Ali, M., Madani, M. T., Butt, F. R., Elhusein, B., Scanavino, M. D. T., Khoodoruth, M. A. S., Sharma, V., & Makki, I. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122421
Xiao, K., Woo, Y., Dri, C. E., Le, G. H., Wong, S., Teopiz, K. M., Zheng, Y. J., Lo, H. K. Y., van Bruggen, F. H., Rhee, T. G., et al. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117456
Self-citationÇelik, D., & Akkuş, M. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002268
Disease-modifying interventions in psychiatry
Baldes, A., Tay, E., Agustini, B., Dodd, S., & Berk, M. P. (2026) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674261493034
Metadata
- Authors
- McIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C.
- Corresponding author
- McIntyre, RS
- ORCID
- Harrison, J
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-15
- Volume
- 19
- Issue
- 10
- Pages
- pyw055
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5091829
- OpenAlex
- W2436735416
- Cited by
- 185
- References
- 44
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 17 · 2023: 14 · 2022: 25 · 2021: 23 · 2020: 20 · 2019: 27 · 2018: 17 · 2017: 15 · 2016: 5
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- HighWire Press Open Archive (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Takeda Pharmaceuticals U.S.A.
- H. Lundbeck A/S
- University of California, San Diego
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- vortioxetine, major depressive disorder, cognitive function, cognitive impairment, duloxetine, Digit Symbol Substitution Test, neuropsychological outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.